AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00637923 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
Study NCT00637923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Weight-based ribavirin for 48 weeks.
Study NCT00637923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Weight-based ribavirin for 48 weeks.
Study NCT00867282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-00241939 750ug using inhaler A
Study NCT00867282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: PF-00241939 750ug using inhaler B
Study NCT02097641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells
Description: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
Study NCT02097641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasma-Lyte A
Description: Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
Study NCT02709824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate with ADS
Description: Oral rinsing, twice a day, for 21 days
Study NCT03959891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
Study NCT03959891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
Study NCT03959891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
Study NCT03959891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
Study NCT02709824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate without ADS
Description: Oral rinsing, twice a day, for 21 days
Study NCT00680589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of mouse TYRP2 DNA
Description: Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
Study NCT04047589 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
Description: Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
Study NCT01456039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
Study NCT05990010 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Berlin Questionnaire
Description: The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.
Study NCT01021020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6mg tablet administered after a fast of at least 10 hours
Study NCT01021020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
Study NCT01021020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine/Probenecid
Description: 0.5mg/500mg tablet administered after a fast of at least 10 hours
Study NCT04693819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Somatic modulation
Description: Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application
Study NCT04047589 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations
Description: Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
Study NCT01454518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration of local anesthetic
Description: 30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
Study NCT01454518 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Injection
Description: injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
Study NCT03048643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antibiotic therapy
Description: Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
Study NCT02669420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: termination of second trimester pregnancy
Description: Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
Study NCT00690235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pramlintide
Description: 180mg subcutaneous injections, twice daily
Study NCT00690235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 180mg subcutaneous injections, twice daily
Study NCT04012229 — intervention group
Intervention type: GENETIC
Intervention: BRCA mutation
Description: The genetic testing was performed according interregional consensus (Manchester score > or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
Study NCT04191044 — intervention group
Intervention type: OTHER
Intervention: A complete cardiovascular and liver characterization will be carried out
Description: A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
Study NCT01893437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6799477
Description: Single doses of RO6799477
Study NCT05475652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
Study NCT05475652 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo intervention
Description: The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group
Study NCT03019796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDICATION AND EXERCISE TRAINING
Description: PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE).
Study NCT01491893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Description: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Study NCT02499770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02499770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02499770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Study NCT02499770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02739373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986189
Study NCT02739373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03728413 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RSV A Memphis 37
Description: Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment.
Study NCT01458223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Ancef or Vancomycin
Study NCT01458223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Ancef or Vancomycin
Study NCT00031551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT00031551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02637973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25 mg once daily
Study NCT02637973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT02675868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
Study NCT02675868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
Study NCT02675868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressins
Description: Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
Study NCT02675868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9% infusion
Study NCT00390585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol 320
Description: Iodixanol 320 is used as contrast media while coronary intervention.
Study NCT00390585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iomeprol 350
Description: Iomeprol 350 is used as contrast media while coronary intervention.
Study NCT02050152 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Explicit and Implicit memory
Description: Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
Study NCT02050152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Explicit and Implicit memory
Description: Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
Study NCT02050152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide
Study NCT02050152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide
Study NCT02037841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing-driven clinical pathway for management of inpatient asthma
Study NCT02334774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swallowing and Oral Care Program
Description: An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
Study NCT02882724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8-week aquatic exercise training program
Study NCT02882724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group did not do the exercise training.
Study NCT03674463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCAR-B4822M CAR-T Cell Immunotherapy
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
Study NCT04758689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Laser, exercise, and methotrexate
Description: Laser therapy at acupuncture points, aerobic exercise, and methotrexate
Study NCT04758689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exercise, and methotrexate
Description: Aerobic exercise, and methotrexate
Study NCT03171077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Rehabilitation
Description: It is the use of the NW games for rehabilitation of balance in post-stroke patients.
Study NCT03171077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Method
Description: It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
Study NCT03171077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Rehabilitation and PNF Method
Description: It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
Study NCT02304796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Cognitive-Behavioral Therapy
Description: 20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention.
Study NCT02304796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive-Behavioral and Dance/Movement Therapy
Description: 20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
Study NCT01319188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg of ranibizumab
Description: Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
Study NCT01319188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg of ranibizumab + photodynamic therapy
Description: Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
Study NCT01319188 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
Study NCT02680002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 mcg H5N1 (stored as monobulk)
Study NCT02680002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 mcg H5N1 (stored as monobulk)
Study NCT02680002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 mcg H5N1 (stored as monobulk)
Study NCT02680002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 mcg H5N1 (stored in vials)
Study NCT02680002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59
Study NCT02680002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59 (stored as monobulk)
Study NCT03572478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600 mg taken by mouth twice daily.
Study NCT03572478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg given by intravenous (IV) infusion every 4 weeks.
Study NCT03527173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.sonnei vaccine
Description: Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
Study NCT03527173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
Study NCT03527173 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: S. sonnei 53G challenge strain
Description: Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
Study NCT03527173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 53G challenge strain
Description: Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
Study NCT03790319 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Power of Feelings
Description: Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion.
Study NCT03790319 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Emotional Backpack
Description: One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion.
Study NCT03818685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Radiotherapy will be maintained in each Arm.